PTPRC and diffuse large B-cell lymphoma: Removal of gal-3 from CD45 on the cell surface with the multivalent glycan inhibitor GCS-100 increased the sensitivity of DLBCL cells to chemotherapeutic agents.178 This sheds light on the importance of specific glycosylation of CD45 in regulating gal-3 pathway signaling and implication in DLBCL chemotherapy treatment.